Grandfield & Dodd, LLC Vertex Pharmaceuticals Inc Transaction History
Grandfield & Dodd, LLC
- $1.58 Billion
- Q3 2024
A detailed history of Grandfield & Dodd, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 14,144 shares of VRTX stock, worth $6.22 Million. This represents 0.42% of its overall portfolio holdings.
Number of Shares
14,144
Previous 11,606
21.87%
Holding current value
$6.22 Million
Previous $5.44 Million
20.94%
% of portfolio
0.42%
Previous 0.36%
Shares
28 transactions
Others Institutions Holding VRTX
# of Institutions
1,707Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$11.8 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.2 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.37 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.19 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.96 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $113B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...